| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2101 [S. E. L., D. S. C.], and Gilead Sciences, Boulder, Colorado 80301 [B. J. H., Y. L.].
We have identified two synthetic oligonucleotides (aptamers) that bind to prostate cancer cells,with low nanomolar affinity, via the extracellular portion of the prostate-specificmembrane antigen (PSMA). These two specific aptamers were selected from an initial 40mer library of 
6 x 1014 random-sequence RNA molecules for their ability to bind to a recombinant protein representing the extracellular 706 amino acids of PSMA, termed xPSM. Six rounds of in vitro selection were performed, enriching for xPSM binding as monitored by aptamer inhibition of xPSM N-acetyl-
-linked acid dipeptidase (NAALADase) enzymatic activity. By round six, 95% of the aptamer pool consisted of just two sequences. These two aptamers, termed xPSM-A9 and xPSM-A10, were cloned and found to be unique, sharing no consensus sequences. The affinity of each aptamer for PSMA was quantitated by its ability to inhibit NAALADase activity. Aptamer xPSM-A9 inhibits PSMA noncompetitively with an average Ki of 2.1 nM, whereas aptamer xPSM-A10 inhibits competitively with an average Ki of 11.9 nM. Distinct modes of inhibition suggest that each aptamer identifies a unique extracellular epitope of xPSM. One aptamer was truncated from 23.4 kDa to 18.5 kDa and specifically binds LNCaP human prostate cancer cells expressing PSMA but not PSMA-devoid PC-3 human prostate cancer cells. These are the first reported RNA aptamers selected to bind a tumor-associated membrane antigen and the first application of RNA aptamers to a prostate specific cell marker. These aptamers may be used clinically as NAALADase inhibitors or be modified to carry imaging agents and therapeutic agents directed to prostate cancer cells.
This article has been cited by other articles:
|
|
 |
|
  S. Dhar, F. X. Gu, R. Langer, O. C. Farokhzad, and S. J. Lippard Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles PNAS, November 11, 2008; 105(45): 17356 - 17361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, and O. C. Farokhzad From the Cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers PNAS, February 19, 2008; 105(7): 2586 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rege, S. J. Patel, Z. Megeed, and M. L. Yarmush Amphipathic Peptide-Based Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate Cancer Cells Cancer Res., July 1, 2007; 67(13): 6368 - 6375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Ellington, J. Ebright, T. Chu, and M. Levy Using Aptamers for Cell-Specific Labeling and Delivery Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 51 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, H. J. Lee, and R. M. Corn Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging Nucleic Acids Res., December 2, 2006; 34(22): 6416 - 6424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Coffey, R. H. Getzenberg, and T. L. DeWeese Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". JAMA, July 26, 2006; 296(4): 445 - 448. [Full Text] [PDF]
|
|
|
|
|
|
T. C. Chu, J. W. Marks III, L. A. Lavery, S. Faulkner, M. G. Rosenblum, A. D. Ellington, and M. Levy Aptamer:Toxin Conjugates that Specifically Target Prostate Tumor Cells. Cancer Res., June 15, 2006; 66(12): 5989 - 5992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Chu, K. Y. Twu, A. D. Ellington, and M. Levy Aptamer mediated siRNA delivery Nucleic Acids Res., June 1, 2006; 34(10): e73 - e73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo PNAS, April 18, 2006; 103(16): 6315 - 6320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Di Giusto, W. A. Wlassoff, J. J. Gooding, B. A. Messerle, and G. C. King Proximity extension of circular DNA aptamers with real-time protein detection Nucleic Acids Res., April 7, 2005; 33(6): e64 - e64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Farokhzad, S. Jon, A. Khademhosseini, T.-N. T. Tran, D. A. LaVan, and R. Langer Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells Cancer Res., November 1, 2004; 64(21): 7668 - 7672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lupold and R. Rodriguez Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen Mol. Cancer Ther., May 1, 2004; 3(5): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Lee, J. R. Hesselberth, L. A. Meyers, and A. D. Ellington Aptamer Database Nucleic Acids Res., January 1, 2004; 32(90001): D95 - 100. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
